The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report

The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report

BackgroundApproximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with brain metastases (BM), which are associated with poor prognosis. Pembrolizumab has shown promising results in advanced NSCLC with PD-L1 ≥ 50%, including patients with BM. Silibinin is a flavonolignan w...

Full description

Saved in:
Bibliographic Details
Main Authors: Joaquim Bosch-Barrera, Elia Sais, Eduard Teixidor-Vilà, Carmen Vásquez-Dongo, Alejandro Hernandez-Martínez, Alvaro Romera, Mel.lina Pinsach-Abuin, Bernat del Olmo, Glòria Oliveras, Emma Polonio-Alcalá, Sara Verdura, Miriam Soriano-Gamero, Victor Pineda, Hugo Rosales, Javier A. Menendez
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Medicine
Subjects:
silymarin
immunotherapy
natural product
lung adenocarcinoma
brain radiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1612327/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2025.1612327/full

Similar Items